Novavax to Participate in Fireside Chat at Devex @ UNGA 76 - il Centro Tirreno - Quotidiano online
Il sito "il Centro Tirreno.it" utilizza cookie tecnici o assimiliati e cookie di profilazione di terze parti in forma aggregata a scopi pubblicitari e per rendere più agevole la navigazione, garantire la fruizione dei servizi, se vuoi saperne di più leggi l'informativa estesa, se decidi di continuare la navigazione consideriamo che accetti il loro uso.
24
Dom, Ott

Novavax to Participate in Fireside Chat at Devex @ UNGA 76

Immediapress
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

GAITHERSBURG, Md., Sept. 20, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer, will be interviewed at Devex @ UNGA

76 on September 21 at 8:50 a.m. The event is hosted by the media outlet Devex and is taking place September 21-23 via livestream as part of its coverage of the 76th meeting of the United Nations General Assembly (UNGA 76). Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion along with fostering global vaccine access. 

Interview details are as follows: 

For more information or to register for the fireside chat, visit:https://pages.devex.com/devex-at-unga-76.html  

About NovavaxNovavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. 

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn. 

Contacts:     InvestorsNovavax, Inc.Erika Schultz | Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.  

Solebury TroutAlexandra Roy | Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.  

MediaAlison Chartan | 240-720-7804Laura Keenan | Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.  

Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg